You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

R/M head and neck squamous cell carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma Trial (Ficlatuzumab,

Not yet recruiting
  • Metastatic Head-and-neck Squamous-cell Carcinoma
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Ficlatuzumab
  • +2 more
  • (no location specified)
Sep 26, 2023

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Trial in Shanghai (Dalpiciclib+cetuximab)

Recruiting
  • Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
  • Shanghai, Shanghai, China
    the Ninth People's Hospital Affiliated to Shanghai Jiao Tong Uni
Feb 9, 2023

Head and Neck Squamous Cell Carcinoma Trial in Candiolo (inulin, Pembrolizumab, Nivolumab)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • inulin
  • +2 more
  • Candiolo, Turin, Italy
    Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo
Apr 7, 2023

Head and Neck Squamous Cell Carcinoma Trial in Taipei (Ribociclib, Spartalizumab)

Active, not recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Taipei, Taiwan
    National Taiwan University Hospital
Apr 19, 2022

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Trial in Pittsburgh (Pembrolizumab, Carboplatin,

Not yet recruiting
  • Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 18, 2023

Head and Neck Tumors, Carcinoma, Squamous Cell of Head and Neck, Metastasis Trial in Hospitalet de Llobregat, Barcelona (VCN-01,

Active, not recruiting
  • Head and Neck Neoplasms
  • +3 more
  • VCN-01
  • Durvalumab
  • Hospitalet de Llobregat, Barcelona, Spain
  • +1 more
Mar 25, 2022

Pembrolizumab in the First Line Therapy for R/M HNSCC in China

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Beijing, China
    Cancer Institute/Hospital, Chinese Academy of Medical Sciences &
Feb 4, 2022

First Line Recurrent/Metastatic Squamous Cell Carcinoma of Head

Completed
  • Squamous Cell Carcinoma of the Head and Neck
    • Parsippany, New Jersey
      Medical Data Analytics
    Nov 15, 2021

    Head and Neck Squamous Cell Carcinoma Trial in Beijing (Pembrolizumab combined with Chemotherapy)

    Recruiting
    • Head and Neck Squamous Cell Carcinoma
    • Pembrolizumab combined with Chemotherapy
    • Beijing, Beijing, China
      National Cancer Center/Cancer Hospitial,Chinese Academy of Medic
    Feb 4, 2022

    Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma Trial in Shanghai

    Recruiting
    • Recurrent Head and Neck Squamous Cell Carcinoma
    • Metastatic Head and Neck Squamous Cell Carcinoma
    • Shanghai, China
      the Ninth People's Hospital Affiliated to Shanghai Jiao Tong Uni
    Dec 5, 2021

    Head and Neck Tumors, Recurrent Disease, Metastatic Cancer Trial in Shanghai (Penpulimab combined with cetuximab)

    Active, not recruiting
    • Head and Neck Neoplasms
    • +2 more
    • Penpulimab combined with cetuximab
    • Shanghai, China
      Department of Radiotherapy, Eye & ENT Hospital of Fudan Universi
    Mar 1, 2022

    HNSCC Trial in United States (Tipifarnib, Alpelisib)

    Recruiting
    • HNSCC
    • Duarte, California
    • +10 more
    Jun 30, 2022

    Head and Neck Squamous Cell Carcinoma Trial (Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab)

    Not yet recruiting
    • Head and Neck Squamous Cell Carcinoma
    • (no location specified)
    Oct 9, 2023

    Recurrent Head and Neck Squamous Cell Carcinoma, Head Neck Cancer Stage IV Trial in Spain (Nivolumab + Paclitaxel, Cetuximab +

    Active, not recruiting
    • Recurrent Head and Neck Squamous Cell Carcinoma
    • Head and Neck Cancer Stage IV
    • Nivolumab + Paclitaxel
    • Cetuximab + Paclitaxel
    • Santander, Cantabria, Spain
    • +20 more
    Aug 2, 2022

    Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma Trial in Chengdu (Camrelizumab, Dalpiciclib 100mg,

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • Head and Neck Squamous Cell Carcinoma
    • Chengdu, Sichuan, China
      West China Hospital, Sichuan University
    Oct 25, 2023

    Oropharyngeal Cancer Trial in Canada (Radiation, Cisplatin)

    Active, not recruiting
    • Oropharyngeal Cancer
    • Prince George, British Columbia, Canada
    • +13 more
    Dec 12, 2022

    Head and Neck Squamous-cell Carcinoma

    Not yet recruiting
    • Squamous Cell Carcinoma of Head and Neck
    • +2 more
      • (no location specified)
      Nov 5, 2023

      Needs and Preferences of Patients With Head-neck Cutaneous SCC

      Active, not recruiting
      • Cutaneous Squamous Cell Carcinoma
      • +10 more
      • Regular care with additional administration of a semi-structured interview
      • Maastricht, Netherlands
        Maastricht University Medical Center+
      Sep 13, 2023

      Head and Neck Squamous Cell Carcinoma Trial in Guangzhou (Nab paclitaxel, Carboplatin, adelbelimumab)

      Not yet recruiting
      • Head and Neck Squamous Cell Carcinoma
      • Nab paclitaxel
      • +2 more
      • Guangzhou, Guangdong, China
        Sun Yat-sen Memorial Hospital
      Aug 24, 2023

      Head and Neck Squamous Cell Carcinoma Trial in Beijing (Pembrolizumab, Anlotinib)

      Recruiting
      • Head and Neck Squamous Cell Carcinoma
      • Beijing, Beijing, China
        National Cancer Center/Cancer Hospitial,Chinese Academy of Medic
      Aug 2, 2021

      Head and Neck Squamous Cell Carcinoma, PET/CT Trial (Neck dissection)

      Not yet recruiting
      • Head and Neck Squamous Cell Carcinoma
      • PET/CT
      • Neck dissection
      • (no location specified)
      Jan 31, 2023

      Head and Neck Squamous Cell Carcinoma, Head Neck Cancer Trial (Tislelizumab, BGB-A425, LBL-007)

      Not yet recruiting
      • Head and Neck Squamous Cell Carcinoma
      • Head and Neck Cancer
      • (no location specified)
      Jun 9, 2023

      Prognostic Immune Biomarkers in HNSCC

      Completed
      • Head and Neck Cancer
      • Squamous Cell Carcinoma
      • Tumour immunoprofile evaluation
      • Ostrava, Moravian-Silesian Region, Czechia
        University Hospital Ostrava
      Jul 3, 2023

      Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Trial (Nimotuzumab, Sintilimab, Chemotherapy drug)

      Not yet recruiting
      • Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
      • (no location specified)
      May 6, 2021

      Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck

      Not yet recruiting
      • Squamous Cell Carcinoma of Head and Neck
      • +2 more
      • RP3
      • +3 more
      • (no location specified)
      Feb 21, 2023